PDCD1 and in situ carcinoma: In contrast, the high-risk group is linked with molecular subtypes with poor survival for coding and non-coding RNA, which are further associated with lymphocyte infiltration, the high expression of CIS (carcinoma in situ) signature genes, CD274 (PD-L1) and PDCD1 (PD-1) levels, high TP53 mutations and EMT scores [17].